Clinical Trial Update: A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of the selective CDK inhibitor P1446A-05 in adults with advanced refractory solid tumors or hematologic malignancies has been completed, accordi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Solid Tumor

Drugs mentioned

• P1446A-05

Snippet

Sponsor: Piramal Enterprises Limited | Conditions: Solid Tumor, Hematologic Malignancy | Phase 1 | Status: COMPLETED